Exelixis, Inc. (NASDAQ:EXEL) Director Stelios Papadopoulos sold 10,000 shares of the stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $25.40, for a total transaction of $254,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Stelios Papadopoulos also recently made the following trade(s):

  • On Monday, September 18th, Stelios Papadopoulos sold 72,210 shares of Exelixis stock. The stock was sold at an average price of $27.76, for a total transaction of $2,004,549.60.
  • On Tuesday, September 19th, Stelios Papadopoulos sold 200,000 shares of Exelixis stock. The stock was sold at an average price of $27.68, for a total transaction of $5,536,000.00.

Exelixis, Inc. (NASDAQ:EXEL) traded down 12.64% on Friday, hitting $24.47. 10,840,029 shares of the company’s stock were exchanged. The stock has a market cap of $7.19 billion, a P/E ratio of 123.59 and a beta of 1.97. The firm has a 50 day moving average price of $27.08 and a 200-day moving average price of $23.49. Exelixis, Inc. has a 52-week low of $10.04 and a 52-week high of $29.50.

Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.02. The firm had revenue of $99.01 million for the quarter, compared to the consensus estimate of $85.27 million. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The company’s revenue was up 173.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.15) EPS. Analysts predict that Exelixis, Inc. will post $0.27 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Exelixis, Inc. (EXEL) Director Sells $254,000.00 in Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/22/exelixis-inc-exel-director-sells-254000-00-in-stock.html.

Several research analysts recently issued reports on EXEL shares. TheStreet raised shares of Exelixis from a “c” rating to a “b-” rating in a research note on Monday, August 7th. BidaskClub raised shares of Exelixis from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. SunTrust Banks, Inc. initiated coverage on shares of Exelixis in a research note on Thursday, July 13th. They set a “buy” rating and a $33.00 target price on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a research note on Thursday, August 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price objective (up from $28.00) on shares of Exelixis in a research note on Tuesday, September 12th. Six research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Exelixis currently has an average rating of “Buy” and a consensus target price of $26.51.

Several large investors have recently added to or reduced their stakes in the company. FMR LLC grew its position in shares of Exelixis by 2.0% in the 2nd quarter. FMR LLC now owns 43,748,695 shares of the biotechnology company’s stock worth $1,077,530,000 after buying an additional 857,452 shares during the period. Vanguard Group Inc. grew its position in shares of Exelixis by 7.2% in the 2nd quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock worth $626,635,000 after buying an additional 1,706,893 shares during the period. Meditor Group Ltd grew its position in shares of Exelixis by 5.5% in the 2nd quarter. Meditor Group Ltd now owns 20,229,713 shares of the biotechnology company’s stock worth $498,258,000 after buying an additional 1,046,000 shares during the period. BlackRock Inc. grew its position in shares of Exelixis by 33,678.5% in the 1st quarter. BlackRock Inc. now owns 19,155,466 shares of the biotechnology company’s stock worth $415,099,000 after buying an additional 19,098,757 shares during the period. Finally, Matrix Capital Management Company LP grew its position in shares of Exelixis by 8.8% in the 2nd quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock worth $372,343,000 after buying an additional 1,225,000 shares during the period. 79.20% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.